M. P. Goren

发表

D. A. Bush, W. Brade, J. Houle, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tubular nephrotoxicity during long-term ifosfamide and mesna therapy

C. Pratt, M. Viar, M. P. Goren, 2004, Cancer Chemotherapy and Pharmacology.

Oral mesna: a review.

M. P. Goren, Marshall P. Goren, 1992, Seminars in oncology.

Urinary N-acetyl-beta-D-glucosaminidase and serum creatinine concentrations predict impaired excretion of methotrexate.

W. Meyer, R. K. Wright, M. Horowitz, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.

R. Natale, A. Forastiere, M. P. Goren, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin nephrotoxicity affects magnesium and calcium metabolism.

M. P. Goren, 2003, Medical and pediatric oncology.

Cumulative renal tubular damage associated with cisplatin nephrotoxicity

R. K. Wright, M. Horowitz, M. P. Goren, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients.

M. Posner, A. Forastiere, J. Belliveau, 1988, Cancer research.

Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna.

C. Pratt, R. K. Wright, M. Horowitz, 1987, Cancer treatment reports.

Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.

R. Dodge, W. Meyer, C. Pratt, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DECHLOROETHYLATION OF IFOSFAMIDE AND NEUROTOXICITY

C. Pratt, R. K. Wright, M. P. Goren, 1986, The Lancet.

The stability of mesna in beverages and syrup for oral administration

M. P. Goren, B. A. Lyman, Jackie T. Li, 1991, Cancer Chemotherapy and Pharmacology.

Mesna excretion and ifosfamide nephrotoxicity in children.

R. Dodge, W. Meyer, C. Pratt, 1989, Cancer research.

Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor

D. A. Bush, R. Quigley, S. Weitman, 1997, Cancer Chemotherapy and Pharmacology.

Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children.

D. Baker, J. Shenep, M. P. Goren, 1989, The Pediatric infectious disease journal.

Combined intravenous and oral mesna in outpatients treated with ifosfamide

T. L. Goodman, M. P. Goren, Linda M. McKenna, 1997, Cancer Chemotherapy and Pharmacology.

Monitoring serum aminoglycoside concentrations in children with amphotericin B nephrotoxicity.

D. Baker, J. Shenep, R. K. Wright, 1988, The Pediatric infectious disease journal.

Use of somatic cell hybrids to analyze role of specific enzymes in daunorubicin cytotoxicity.

Marshall P. Goren, A. Tereba, N. Ahmed, 1987, Cancer research.

Two AutomatedProceduresfor N-Acetyl-f3-o-glucosaminidase Determination Evaluatedfor Detectionof Drug-InducedTubularNephrotoxicity

R. K. Wright, M. P. Goren, S. Osborne, 1986 .

False-positive ketone tests: a bedside measure of urinary mesna

C. Pratt, M. P. Goren, 2004, Cancer Chemotherapy and Pharmacology.

Ifosfamide in pediatric malignant solid tumors

E. Douglass, W. Meyer, C. Pratt, 2004, Cancer Chemotherapy and Pharmacology.

Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.

R. Dodge, C. Pratt, Marshall P. Goren, 1987, Cancer research.

A peroxidase-coupled kinetic enzymatic procedure evaluated for measuring serum and urinary creatinine.

R. K. Wright, M. P. Goren, S. Osborne, 1986, Clinical chemistry.

Two automated procedures for N-acetyl-beta-D-glucosaminidase determination evaluated for detection of drug-induced tubular nephrotoxicity.

R. K. Wright, M. P. Goren, S. Osborne, 1986, Clinical chemistry.

Enhancement of methotrexate nephrotoxicity after cisplatin therapy

W. Meyer, R. K. Wright, M. Horowitz, 1986, Cancer.

Increased tubular enzyme excretion in preeclampsia.

B. Sibai, M. P. Goren, A. El-Nazar, 1987, American journal of obstetrics and gynecology.

The Coomassie Brilliant Blue method underestimates drug-induced tubular proteinuria.

M. P. Goren, J. T. Li, 1986, Clinical chemistry.

Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity

R. Dodge, C. Pratt, A. Forastiere, 2004, Cancer Chemotherapy and Pharmacology.

Increased tubular enzyme excretion in preeclampsia

B. Sibai, M. P. Goren, A. El-Nazar, 1988 .

Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography.

M. P. Goren, 1991, Journal of chromatography.

Reduction of dimesna to mesna by the isolated perfused rat liver.

M P Goren, L C Hsu, J T Li, 1998, Cancer research.

Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein.

C. Pratt, R. K. Wright, M. Horowitz, 1986, American journal of clinical pathology.

Increased levels of urinary adenosine deaminase binding protein in children treated with cisplatin or methotrexate.

R. K. Wright, M. Horowitz, M. P. Goren, 1986, Clinica chimica acta; international journal of clinical chemistry.

Agarose gel electrophoresis in isozyme separation and visualization

J. Hunt, A. Tereba, M. P. Goren, 1989, Biochemical Genetics.

Extending the linear range for kinetic reactions by considering the relationship between enzyme activity of the reagent and measurement intervals.

J. Davis, M. P. Goren, 1986, Clinical chemistry.